Please call your physician’s office before coming in for your appointment if you have symptoms of a cough, fever, or difficulty breathing; traveled to Europe or China or other areas impacted by the coronavirus (COVID-19) within the past 14 days; been in close contact with someone who has traveled outside the U.S. to one of the impacted countries; or may have been exposed to the coronavirus.  For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Our new office hours are: Monday through Friday 8:30 a.m. to 4:00 p.m, if you have an appointment scheduled for after hours, our office will be contacting you directly to reschedule. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

Gregory J Orloff, MD

VCS Physicians

Gregory J Orloff, MD Headshot

As part of the Oncology Care Model (OCM), we are dedicated to providing patients with the best possible experience at Virginia Cancer Specialists. It is our duty to ensure that each patient has an excellent understanding of their treatment plan, timely manage their symptoms and emotional needs, and assist each in the navigation of all additional services that may be required. We also understand that your family is most important in your care and quality of life. It is our commitment to include them according to your wishes.

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist

Board Certification

Medical Oncology, Hematology and Internal Medicine

Fellowship

Brigham and Women's Hospital at Harvard Medical School, Medical Oncology and Hematology

Internship

Brigham and Women's Hospital at Harvard Medical School

Residency

Brigham and Women's Hospital at Harvard Medical School

Medical School

Yale Medical School

College

Grinnell College

Gregory J. Orloff, MD, received his medical degree from the Yale University School of Medicine where he was also selected as a member of the Alpha Omega Alpha honor society. He completed his medical internship, residency and hematology/oncology fellowship at the Brigham and Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Dr. Orloff was also a Howard Hughes Medical Institute Research Fellow at the Brigham and Women’s Hospital. At the conclusion of his training, he joined the faculty in the Hematology/Oncology division at the Brigham and Women’s Hospital at Harvard Medical School.

Dr. Orloff is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Orloff has been recognized as a Top Doctor by Washingtonian magazine for more than ten years, and he has also been featured on the prestigious “Castle Connolly Top Doctors” list.

Dr. Orloff joined Virginia Cancer Specialists (VCS) in 1995. He had co-directed the Stem Cell Transplant Program in partnership with INOVA Fairfax Hospital. Virginia Cancer Specialists is a member of the Multiple Myeloma Research Consortium (MMRC), for which Dr. Orloff is the site director and principal investigator. Dr. Orloff is currently an Assistant Professor, in the Department of Oncology at Johns Hopkins University.

 


Practice Blog

October 16, 2018

The Multiple Myeloma Research Foundation (MMRF) Patient Weekend Photo Albums and a Special Thanks

Read More
September 30, 2018

Join Virginia Cancer Specialists for a Weekend of Learning and Engaging MMRF PATIENT WEEKEND Washington D.C.

Read More

Clinical Trials (6)

Clinical Trial 18-255-02

A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGE REGIMEN FOR MULTIPLE MYELOMA


Clinical Trial 18028

A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine in Patients with MDS (TPI-ALV-102)


Clinical Trial 19064

A PHASE Ia/Ib OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF TIRAGOLUMAB AS A SINGLE AGENT AND IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, AND AS A SINGLE AGENT AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.(GO41036)


Clinical Trial MMRC-085

Myeloma-Developing Regimens Using Genomics (MyDRUG)(Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen)


Clinical Trial Cartesian 2415988

Autologous CD8+ T-cells Transiently Expressing an Anti-BCMA CAR in Patients With Myeloma


Clinical Trial MMRF-002

Clinical-grade Molecular Profiling of Patients with Multiple and Related Plasma Cell Malignancies

Primary Location

Fairfax Office Office

Fairfax Office

Learn More

Awards

January 1, 2019

Northern VA Magazine Top Doctors


January 1, 2018
Top Doctors Virginia Living Magazine 2018

Top Doctors Virginia Living Magazine 2018


January 1, 2018
Northern Virginia Magazine Top Doctors 2018

Northern Virginia Magazine Top Doctors 2018


September 9, 2016
Washingtonian Magazine

Washingtonian Top Doctor 2016